Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cefuroxime Bismuth Quadruple Therapy for H. pylori Rescue
NCT04723472Suspended
- Sponsor
- Shanghai East Hospital
- Start
- Aug 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of cefuroxime in Helicobacter pylori infection (2 arms), sponsored by Shanghai East Hospital. Primary endpoint: Comparison of success rates after 14 days of eradicate treatment. Started Aug 2023; status: suspended.
02
Drugs
cefuroxime
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT04723472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04723472.